Table 2. Tumor response in pMMR and all-comer populations.
| Tumor response | pMMR | All-comer | ||||
|---|---|---|---|---|---|---|
| Lenvatinib+pembrolizumab (n=66) | TPC (n=68) | Lenvatinib+pembrolizumab (n=77) | TPC (n=78) | |||
| ORR* | ||||||
| % (95% CI) | 36 (25–49) | 22 (13–34) | 39 (28–51) | 21 (12–31) | ||
| BOR* | ||||||
| No. (%) | ||||||
| CR | 6 (9.1) | 3 (4.4) | 9 (11.7) | 4 (5.1) | ||
| PR | 18 (27.3) | 12 (17.6) | 21 (27.3) | 12 (15.4) | ||
| SD | 25 (37.9) | 25 (36.8) | 28 (36.4) | 30 (38.5) | ||
| PD | 17 (25.8) | 22 (32.4) | 18 (23.4) | 24 (30.8) | ||
| Not evaluable† | 0 (0.0) | 1 (1.5) | 0 (0.0) | 1 (1.3) | ||
| No assessment‡ | 0 (0.0) | 5 (7.4) | 1 (1.3) | 7 (9.0) | ||
| DOR (mo) | ||||||
| Median (range) | 14.4 (1.6 to 39.5+) | 5.2 (2.1+ to 37.1+) | 16.5 (1.6 to 39.5+) | 5.2 (1.9+ to 37.1+) | ||
+, no PD by time of last assessment; BOR, best overall response; CR, complete response; DOR, duration of response; ORR, objective response rate; PD, progressive disease; pMMR, mismatch repair proficient; PR, partial response; SD, stable disease; TPC, treatment of physician’s choice chemotherapy.
*Per Response Evaluation Criteria in Solid Tumors version 1.1 by blinded independent central review.
†Postbaseline assessment(s) available but not evaluable.
‡No postbaseline assessment available for response evaluation.